- Delivering on its promise during the COVID-19 pandemic to its patients, partners, and communities around the world
Lotus Pharmaceuticals Co., Ltd (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795)today announced that it made a voluntary donation of 10,000 packs chloroquine phosphate to Thai Ministry of Public Health to assist local government with possible solutions to COVID-19.
Lotus has been proactively monitoring changes and developments and taking all measures to mitigate any interruption since the outbreak. It has created procedures to ensure the health and safety of the employees to make sure that the team can continue to operate at the capacity needed, especially in its manufacturing sites in both Taiwan and Korea, and tracks the process on regular and ad hoc basis.
Lotus is an Alvogen Company with high-value, complex generic products specializing in oncology, CNS, CVS, women health, and anti-obesity drugs. Headquartered in Taiwan, Lotus has been building commercial platforms across APAC since Alvogen’s majority investment in 2014 and successfully transformed to be Alvogen’s regional hub in Asian markets. In addition to its current direct markets in Taiwan and Korea, Lotus is also developing SEA markets, including Thailand and Vietnam, by consolidating Alvogen’s local infrastructure to offer more resourceful services on a well-established platform in all countries across the region. By aligning the Company’s internal best-in-class development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike.